<DOC>
	<DOCNO>NCT01078922</DOCNO>
	<brief_summary>This phase II open label study look efficacy toxicity Ofatumumab monotherapy patient relapse and/or refractory diffuse large B-cell lymphoma ( DLBCL ) . Patients receive weekly infusion Ofatumumab 1000 mg 8 week ( induction phase ) follow continue study drug every week subsequent cycle ( maintenance phase ) . Each 4 week therapy calculate one cycle . Treatment continue disease progression , toxicity , patient 's withdrawal , investigator 's discretion .</brief_summary>
	<brief_title>Patients With Relapsed Refractory Diffuse Large B Cell Non Hodgkin Lymphomas</brief_title>
	<detailed_description>Ofatumumab fully human monoclonal IgG1κ-antibody target novel cluster differentiation antigen 20 ( CD20 ) -epitope . Preclinical data show ofatumumab active B-cell lymphoma/chronic lymphocytic leukemia cell-lines low CD20-antigen density increase expression complement inhibitory molecule . Ofatumumab superior rituximab ability induce lysis B-cell line also kill fresh B-chronic lymphocytic leukemia cell resistant rituximab . Ofatumumab slow off-rate stable CD20 bind comparison rituximab target different epitope CD20 antigen rituximab [ Teeling , 2004 , Teeling , 2006 ] . In cynomolgus monkey , duration B-cell depletion peripheral blood lymph node induce ofatumumab longer rituximab [ Dechant , 2003 ] . Ofatumumab 's ability induce complement-dependent cytotoxicity ( CDC ) specifically study isolated lymphoma cell chemotherapy refractory DLBCL patient [ Cillessen , 2007 ] . Ofatumumab rituximab induce CDC DLBCL sample test , include DLBCL cell line SUDHL-4 , SUDHL-5 HT lymphoma cell derive ten chemotherapy-refractory DLBCL patient . Ofatumumab significantly effective induce CDC nine ten DLBCL tumor sample compare rituximab ( p=0.001 ) . The lethal dos ( LD50 ) ofatumumab ( 0.1 ± 2.8 μg/mL ) significantly low compare LD50 rituximab ( 6.4 ± 4.9μg/mL , p=0.04 ) . Sensitivity DLBCL patient cell ofatumumab- rituximab-induced CDC negatively correlate expression complement defense molecule CD59 , expression CD46 CD55 . Functional inhibition CD55 CD59 use block mAb demonstrate ofatumumab-induced CDC DLBCL tumor cell less sensitive expression complement defense molecules rituximab-induced CDC . Thus , chemotherapy-refractory DLBCL case sensitive CD20 mAb-induced CDC ofatumumab effective mAb , especially patient express high level CD59 . Safety efficacy ofatumumab , analyzed multicenter dose-escalating phase I/II study chronic lymphocytic leukemia ( CLL ) follicular lymphoma ( FL ) . Three cohort patient include 33 patient relapsed refractory CLL receive weekly infusion ofatumumab four week follow : cohort A , first infusion 100 mg three subsequent infusion 500 mg ; cohort B , first infusion 300 mg three subsequent infusion 1000 mg ; cohort C , first infusion 500 mg three subsequent infusion 2000 mg . The maximum tolerate dose reach . The majority related adverse event occur first infusion , number adverse event decrease subsequent infusion . Seventeen ( 51 % ) 33 patient experienced infection , 88 % grade 1-2 . One event interstitial pneumonia fatal ; case resolve within one month . The response rate cohort C 50 % ( 13/26 patient ) [ Coiffier , 2008 ] . Interim data single arm study refractory CLL present ASH 2008 [ Osterborg , 2008 ] . The activity ofatumumab evaluate 138 patient refractory CLL : 59 refractory fludarabine alemtuzumab ( double-refractory : DR ) 79 refractory fludarabine consider inappropriate candidate alemtuzumab due bulky tumor lymph node ( bulky fludarabine-refractory : BFR group ) . Patients receive 8 weekly infusion ofatumumab follow 4 monthly infusion . The first dose 300mg , dose 2-12 2000 mg . Median time next CLL therapy 9 month DR group 8 month BFR group . The median overall survival 14 month DR group 15 month BFR group . Response week 12 significantly correlate long survival group . Ofatumumab associate infusion-related adverse event first infusion day 46 % patient DR group 38 % BFR group , grade 3 7 % 3 % event , respectively . There grade 4 infusion-related event . These event generally subside subsequent infusion . The common grade 3 4 toxicity infection ( 25 % DR ; 27 % BFR group ) hematologic event include neutropenia ( 12 % DR ; 10 % BFR group ) anemia ( 8 % DR ; 4 % BFR group ) . Death within 8 week start treatment occur 2 patient ( 3 % ) DR group ( sepsis , n=1 ; fungal pneumonia , n=1 ) 3 patient ( 4 % ) BFR group ( PD , n=1 ; sepsis , n=1 ; myocardial infarction , n=1 ) . In phase I/II study evaluate safety efficacy ofatumumab relapse refractory FL grade 1-2 , 4 dose-groups 10 patient receive 4 weekly infusion 300 , 500 , 700 , 1000 mg [ Hagenbeek , 2008 ] . Patients median two prior FL therapy 13 % elevated lactate dehydrogenase ( LDH ) . No safety concern maximum tolerate dose identify . Most adverse event occur first infusion day common toxicity criterion ( CTC ) grade 1-2 . Eight related event grade 3 . Treatment cause immediate profound B-cell depletion . The response rate dose dependent ( dose express mg/patient , mg/kg body weight body surface area ( mg/m2 ) ) response obtain 4 dose group ( 300 mg : 5 8 subject ( 63 % ) ; 500 mg : 3 10 subject ( 30 % ) ; 700 mg : 2 10 subject ( 20 % ) ; 1000 mg : 5 10 subject ( 50 % ) . Median time progression ( TTP ) patient 8.8 month . Median TTP responder , duration response , time next anti-FL therapy reach median follow-up 9.2 month . Ofatumumab able induce responses 8 14 patient relapse follow rituximab , include 3 4 rituximab refractory patient . Ofatumumab currently evaluate patient rituximab-refractory FL ( Hx-CD20-405 ) , relapse DLBCL ( GEN-415 ) , rituximab-relapsed/refractory DLBCL combination salvage chemotherapy ( OMB110927 ) phase III trial relapsed/refractory DLBCL ( OMB110928 ) dose 1000mg , combination chemotherapy FL ( Hx-CD20-409 ) dose 500mg 1000mg .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Relapsed and/or refractory DLBCL , HSCT candidate . Pts must fail standard care ( SOC ) therapy w/rituximab plus CHOP equivalent &amp; consider hematopoietic stem cell transplant ( HSCT ) candidate base investigator 's discretion Pts must measurable disease radiographically CT and/or PET scan and/or bone marrow biopsy . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Age ≥18 year . No upper limit age Life expectancy 6 month base investigator 's best estimate . Pts able read , understand , &amp; sign inform consent Evidence CD20 positivity treat pt , use flow immunohistochemistry . Pts stratify base bulk disease ( bulk define area w/ 5cm great dimension ) Pts must agree acceptable form birth control Other histology nonHodgkin 's lymphoma ( NHL ) Known central nervous system ( CNS ) involvement NHL Known HIV positive status Chronic current active infectious disease require systemic antibiotic , antifungal , antiviral treatment . Corticosteroid use allow long nonlymphoma related cause rheumatoid arthritis chronic obstructive pulmonary disease ( COPD ) . Pts w/prior malignancy allow long remission &amp; last treatment malignancy 2 year prior enrollment . Pts w/nonmelanoma skin cancer receive adequate therapy prior enrollment &amp; woman w/history cervical cancer allow . Significant concurrent uncontrolled medical condition include , limited , renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , neurologic , cerebral , psychiatric disease . Current active liver biliary disease ( exception Gilbert 's syndrome asymptomatic gallstone , liver metastasis , otherwise stable chronic liver disease per investigator 's assessment ) . Adequate bone marrow function virtue Platelets &gt; 50,000/ul &amp; absolute neutrophil count ( ANC ) &gt; 1000/ul required unless low count attribute diffuse bone marrow infiltration NHL document bone marrow biopsy exam . Pts creatinine &gt; 2.0 time upper limit normal exclude unless normal creatinine clearanceestimated measure 12 24 hour creatinine clearance &lt; 60 mL/min Pts w/total bilirubin &gt; 1.5 time upper limit normal exclude , unless due DLBCL involvement liver know history Gilbert 's disease . Pts aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) /Alkaline phosphatase ( Alk Phos ) &gt; 2.5 time upper limit normal Previous tx Ofatumumab Prior exposure investigational agent within 4weeks start Ofatumumab History significant cerebrovascular disease event w/significant symptom sequelae Clinically significant cardiac disease include unstable angina , acute myocardial infarction within 6 month prior randomization , congestive heart failure ( NYHA IIIIV ) , &amp; arrhythmia unless control therapy , w/exception extra systole minor conduction abnormality . Positive serology hepatitis B ( HB ) define positive test HBsAg . In addition , negative HBsAg HBcAb positive &amp; regardless HBsAb status , HB DNA test perform positive subject exclude . Note : If HBcAb positive HBsAb positive , indicative past infection , subject include Positive serology hepatitis C ( HC ) define positive test HCAb , case reflexively perform HC RIBA immunoblot assay sample confirm result . Pregnant lactating woman . Women childbearing potential must negative pregnancy test screening , include woman whose last menstrual period less 1 year prior screening , unable unwilling use adequate contraception study start 1 year last dose protocol therapy . Adequate contraception define hormonal birth control , intrauterine device , double barrier method total abstinence .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>ofatumumab diffuse B cell non hodgkins lymphoma DLBCL</keyword>
	<keyword>refractory DLBCL</keyword>
	<keyword>relapse DLBCL</keyword>
</DOC>